Document Detail

Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin.
MedLine Citation:
PMID:  20837094     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To generate a comprehensive map of the drug sensitivity of chronic lymphoid leukemia cells (CLL) using a newly developed in vitro drug-sensitivity assay based on automated evaluation of cell viability on single-cell level.
MATERIALS AND METHODS: Primary CLL cells from 77 patients were tested using automated digital fluorescence microscopy. The effect of 27 frequently used chemotherapeutic agents was measured in short-term fluorescence survival assay. To avoid typical in vitro artifacts such as growth factor depletion and oxidative damage, the cell were cultured in a novel, total human blood lysate-based medium (OmniSanguine) in order to preserve the composition of growth factor flora and redox conditions of the in vivo environment.
RESULTS: CLL cells from different patients showed considerable heterogeneity in their drug-sensitivity patterns. This pattern was stable even after in vitro activation of cell proliferation. Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases. In addition, daunorubicin and prednisolone showed a strong synergistic effect.
CONCLUSIONS: We suggest that the combination of low-dose daunorubicin and prednisolone might be an additional treatment option for therapy-resistant cases of CLL.
Henriette Skribek; Rita Otvos; Emilie Flaberg; Noemi Nagy; Laszlo Markasz; Staffan Eksborg; Tamas Masszi; Andras Kozma; Emma Adam; Attila Miseta; Eva Klein; Laszlo Szekely
Related Documents :
10081704 - Anion efflux from cytotrophoblast cells derived from normal term human placenta is stim...
2706734 - Effect of cyclosporin a on daunorubicin accumulation in multidrug-resistant p388 leukem...
9719484 - The relationship between modulation of mdr and glutathione in mrp-overexpressing human ...
21479174 - The effects of th17 cytokines on the inflammatory mediator production and barrier funct...
22681974 - The electrical stimulation of carbon nanotubes to provide a cardiomimetic cue to mscs.
23225784 - Novel nanoimaging approach: antibodious polymeric nanolabel for intracellular alpha-fet...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-15
Journal Detail:
Title:  Experimental hematology     Volume:  38     ISSN:  1873-2399     ISO Abbreviation:  Exp. Hematol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-01-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0402313     Medline TA:  Exp Hematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1219-30     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Department of Microbiology, Tumor and Cell Biology and Center for Integrative Recognition in the Immune System, Karolinska Institute, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cell Cycle / drug effects
Cluster Analysis
Daunorubicin / administration & dosage
Doxorubicin / administration & dosage
Epirubicin / administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*,  pathology
Prednisolone / administration & dosage
Reg. No./Substance:
20830-81-3/Daunorubicin; 23214-92-8/Doxorubicin; 50-24-8/Prednisolone; 56420-45-2/Epirubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Auditory hallucinations and the P3a: attention-switching to speech in schizophrenia.
Next Document:  A quantum mechanical analysis of the light-harvesting complex 2 (LH2) from purple photosynthetic bac...